Drug · Monoclonal Antibody

Conatumumab

CI-DRUG-00000162Explore in graph →NCIt C71015 CHEMBL1743003 CIViC Phase 2

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	11	—	—	2007-06
Malignant Colon Neoplasm	Phase2	Phase 2	2	—	—	2007-10
Malignant Lung Neoplasm	Phase2	Phase 2	3	—	—	2008-01
Malignant Ovarian Neoplasm	Phase2	Phase 2	2	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CASP8 Overexpression1
Conatumumab	Bone Ewing Sarcoma

Clinical trials

Trials with this intervention (11)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–11 of 11 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00630552	QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer	completed	Phase 1 / Phase 2	138	NantCell, Inc.INDUSTRY	1	Oct 17, 2024	clinicaltrials
NCT00819169	QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors	terminated	Phase 1 / Phase 2

Molecule

Record

Kind: Monoclonal Antibody
Mechanism: Tumor necrosis factor receptor superfamily member 10B agonist
Targets: 1 gene
Aliases: AMG 655, Anti-TRAIL Receptor 2 Monoclonal Antibody AMG 655, Conatumumab, Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Receptor Superfamily Member 10b (Death Receptor 5, Trail-R2, CD262 Antigen)), Monoclonal XG1-048 (Arg(Sup 219),Glu(Sup 361),Met(Sup 363))Gamma-1 Heavy Chain (225-215')-Disulphide With Kappa Light Chain (231-231'':234-234'')-Bisdisulphide Dimer, TRAIL-R2 MAB, TRAIL-R2MAB XG1-048, XG1-048

Data updated 4 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.